Gotham Asset Management LLC Purchases New Holdings in Penumbra, Inc. (NYSE:PEN)

Gotham Asset Management LLC acquired a new position in Penumbra, Inc. (NYSE:PEN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,157 shares of the company's stock, valued at approximately $275,000.

Several other institutional investors have also added to or reduced their stakes in PEN. UMB Bank n.a. grew its stake in shares of Penumbra by 57.4% during the fourth quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $46,000 after buying an additional 70 shares during the last quarter. Hurley Capital LLC purchased a new position in Penumbra during the 4th quarter valued at $56,000. Huntington National Bank grew its position in Penumbra by 138.7% in the 4th quarter. Huntington National Bank now owns 265 shares of the company's stock valued at $63,000 after acquiring an additional 154 shares during the last quarter. Mather Group LLC. grew its position in Penumbra by 208.0% in the 4th quarter. Mather Group LLC. now owns 308 shares of the company's stock valued at $73,000 after acquiring an additional 208 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its stake in Penumbra by 25.0% in the fourth quarter. Jones Financial Companies Lllp now owns 375 shares of the company's stock worth $89,000 after purchasing an additional 75 shares during the period. Institutional investors own 88.88% of the company's stock.

Penumbra Stock Up 0.7%

Shares of PEN stock traded up $1.97 during trading hours on Friday, reaching $268.72. 235,921 shares of the company's stock were exchanged, compared to its average volume of 443,992. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The stock's 50 day moving average is $279.68 and its 200-day moving average is $265.17. Penumbra, Inc. has a fifty-two week low of $148.00 and a fifty-two week high of $310.00. The company has a market cap of $10.41 billion, a price-to-earnings ratio of 790.35, a P/E/G ratio of 2.83 and a beta of 0.53.

Penumbra (NYSE:PEN - Get Free Report) last released its earnings results on Wednesday, April 23rd. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.17. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The firm had revenue of $324.14 million for the quarter, compared to the consensus estimate of $315.72 million. During the same period in the prior year, the firm earned $0.41 EPS. The firm's revenue was up 16.3% on a year-over-year basis. Analysts predict that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Insider Buying and Selling at Penumbra

In other news, EVP Johanna Roberts sold 600 shares of the stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $269.11, for a total transaction of $161,466.00. Following the sale, the executive vice president now directly owns 66,353 shares of the company's stock, valued at $17,856,255.83. This represents a 0.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Thomas Wilder sold 360 shares of the stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $264.58, for a total transaction of $95,248.80. Following the sale, the director now directly owns 4,533 shares in the company, valued at approximately $1,199,341.14. The trade was a 7.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 176,696 shares of company stock valued at $50,207,745. 4.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

PEN has been the subject of a number of recent analyst reports. Wall Street Zen lowered shares of Penumbra from a "strong-buy" rating to a "buy" rating in a research note on Saturday. BTIG Research reaffirmed a "buy" rating on shares of Penumbra in a research report on Thursday, April 24th. Canaccord Genuity Group increased their price objective on shares of Penumbra from $323.00 to $340.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Robert W. Baird boosted their price objective on shares of Penumbra from $316.00 to $325.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. Finally, Wells Fargo & Company lifted their price target on Penumbra from $305.00 to $315.00 and gave the company an "overweight" rating in a report on Thursday, April 24th. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $302.40.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.